THERAMetrics will present its innovative Drug Repurposing and Repositioning platform during the Swiss Biotech Day

Stans, Switzerland, March 19, 2014 - Therametrics Holding AG announces the release of DRR 2.0, its innovative Drug Repurposing and Repositioning in-silico platform, delivering significant progress on the research for pharmaceutical molecules and disease indications. Therametrics’ DRR 2.0 service is being offered to the pharmaceutical industry, clinical research organizations, patient associations, research centers, and stakeholders involved in investment projects. “DRR 2.0 is a very effective instrument for searching biological or chemical compounds and exploring all the fundamental biological entities participating in the rationale of mechanisms of actions or biological pathways” said Dorian Bevec, Head of THERAMetrics Discovery. “Our platform elaborates and analyzes more than 22,6 million scientific publications, constituting almost the entire currently accessible, peer-reviewed biomedical literature; from this vast body of globally dispersed, and extremely fragmented information, we investigate a very large spectrum of relevant drugs and diseases – specifically, more than 4900 drugs and 9400 diseases.” Raffaele Petrone, Chairman of the Board of THERAMetrics announced: “With this state of the art technology, we make available a comprehensive and unique service. This technology is for expert scientists and decision makers guiding from the drug to the disease or vice versa through all relevant links in the chain of reasoning, allowing the scientists to explore new possibilities for use of known drugs on diseases and conditions. I am also proud to announce that THERAMetrics’ DRR 2.0 platform will be presented on 8th April 2014 during the Swiss Biotech Day (http://www.biocom.de/de/eventdetails/swiss-biotech-day-2014.html), the leading biotechnology conference in Zürich, Switzerland.” The underlying algorithms, for which patent applications are pending, and technology examples are acknowledged in a recent scientific publication “Graph theory enables drug repurposing – How a mathematical model can drive the discovery of hidden Mechanisms of Action”. The paper is published in the journal PLOS ONE, the largest scientific peer-reviewed journal in the world and is available at the link http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886994/. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0084912 About THERAMetrics THERAMetrics holding AG is a tech-based Contract Research & Development Organisation dedicated to provide a full range of technological solutions through the entire value chain of drug discovery and development. The company, listed at the SIX Swiss Exchange (TMX) and located in Stans (Switzerland). For further information please contact THERAMetrics holding AG Investor and External Relations Tel.: +41 79 285 37 81 [email protected] www.therametrics.com Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning THERAMetrics holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of THERAMetrics holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. THERAMetrics holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.